Author

Steven J. Stanway

ORCID 0000-0002-9739-4290Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:benchmarking· 1 Organism:E. coli· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Katerine Van RietschoteniD· 2 shared Michael J. SkynneriD· 2 shared Paul BeswickiD· 2 shared Adam KirbyiD· 1 shared Adrian J. LloydiD· 1 shared Andrew OweniD· 1 shared Brian McGuinnessiD· 1 shared Catherine E RowlandiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Katerine Van RietschotenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Investigation of anti-SARS CoV-2 multimeric bicyclic peptide inhibitors in a range of pre-clinical therapeutic settings

Maximilian A. J. Harman, Katherine U. Gaynor, Guido Papa, Simone Pellegrino, G.A. Bezerra, Brian McGuinness, Phil Jeffrey, Paul Beswick, Steven J. Stanway, Katerine Van Rietschoten, Liuhong Chen, Ieva Drulyte, Joanne Herriott, Edyta Kijak, Eduardo Gallardo Toledo, , Michael J. Skynner

This paper evaluates the efficacy of multimeric bicyclic peptides as antiviral agents in preclinical SARS-CoV-2 models, showing significant reduction in viral burden across multiple therapeutic settings.

bioRxiv · Oct 3, 2025 · PreprintPharmacology & Toxicology

Discovery and chemical optimisation of a Potent, Bi-cyclic (Bicycle(R)) Antimicrobial Inhibitor of Escherichia coli PBP3

Catherine E Rowland, Hector Newman, Tazmin T. Martin, Rachel Dods, Nikolaos Bournakas, James M. Wagstaff, Nick Lewis, Steven J. Stanway, Matthew R. Balmforth, Celia Kessler, Katerine Van Rietschoten, Dom Bellini, David I. Roper, Adrian J. Lloyd, Christopher Gerard Dowson, , Michael J. Dawson

This study discovers and optimizes bicyclic peptide inhibitors of E. coli PBP3, showing high-affinity binding and broad-spectrum antimicrobial activity.

Communications Biology · May 28, 2025Peer-reviewedBiochemistry